MiRNA let-7b inhibitors by treatment of diabetic retinopathy: evaluation patent US2019093106Journal: Alianzas y Tendencias BUAP (Vol.5, No. 18)
Publication Date: 2020-05-23
Authors : Martin Perez-Santos;
Page : 1-7
Keywords : miRNA let-7b; diabetic retinopathy; patent; diabetes; inhibitor;
Introduction: diabetic retinopathy is a clinical complication that affects to a 93 million people suffering from diabetes and is responsible for more hospitalizations than any other complication of diabetes. Authors of US2019093106 patent propose a method for treatment of diabetic retinopathy. Areas covered: US2019093106 describes a method that consists of the administration of inhibitor of miRNA let-7b, in patients with diabetic retinopathy; additionally describe a method to inhibiting the effects of increased levels or activity of miRNA let-7b. Expert opinion: The results pre-clinical trials support the therapy's efficacy; however, the invention is not new considering art state, whereby, new studies will be necessary to determine other administration routes, e.g. topical, dose and time of administration.
Other Latest Articles
Last modified: 2020-05-23 08:58:13